4564592 toxoplasmosis factor and production of same

PATENT ABSTRACTS 353

4564592 4564597

T O X O P L A S M O S I S F A C T O R A N D P R O D U C T I O N O F S A M E

Hassan Gaafar, Brian Grimwood assigned to Research Corporation

A vaccine for the prevention of congenital Tox- oplasmosis and methods for its production.

A N T I - S M H Y B R I D O M A

Ethan A Lerner, Michael R Lerner assigned to Research Corporation

Anti-Sm antibodies are produced by the hybridoma technique and employed to test for lupus erythematosus in humans.

4564593

M E S S E N G E R R N A , P R O D U C T I O N A N D U S E T H E R E O F

Kyozo Tsukamoto, Shuji Hinuma, Haruo Onda, Toyonaka, Japan assigned to Takeda Chemical Industries Ltd

The present invention provides human Inter- ieukin 2-¢ncording messenger RNA which is free of human cells, a method of producing the same from the cells which are capable of producing human Interleukin 2 and a method of producing human Interleukin 2 using the same in an in vitro protein synthesis system.

4564599

L I P O S O M E C O M P O S I T I O N F O R L U P U S A S S A Y

Andrew S Janoff, Marc J Ostro, Allan L Weiner, Gerald Weissmann, James R Seibold assigned to The Lipodome Company Inc

An assay for detecting SLE antib6dies utilizing a novel liposome composition in which there is en- trapped a divalent cation responsive indicator. The presence of such antibodies is detected by their stabilization of the supermolecular struc- ture of the liposomes. Such stabilization can be detected, and in certain cases, caused by, the ad- dition of magnesium or calcium ions.

4564596

U R O K I N A S E D E R I V A T I V E S C O V A L E N T L Y B O U N D T O

F I B R I N O G E N

Alexandr V Maximenko, Elena G Tischenko, Vladimir P Torchilin, Vladimir Smiruov, Ev- geny I Chazov, Moscow, Union Of Soviet Socialist Republics

Urokinase derivatives comprise urokinase cova- lently bonded with fibrinogen or urokinase cova- lently bonded with fibrinogen through an aliphatic diamine and correspond to the general formula: See Patent for Chemical Structure wherein P is fibrinogen, E is urokinase, R is abs- ent or stands for See Patent for Chemical Struc- ture wherein n is 1-12, with a molecular mass of from 360,000 to 440,000 D, a content of protein of 10 to 30° o by mass, an esterase catalytic ac- tivity of 30-60~h. These derivatives have an in- creased affinity to fibrin and feature a prolonged fibrinolytic effect.

4564600

A L L E R G E N S A N D A N T I B O D I E S F R O M A L L E R G E N E X T R A C T S

A N D P O O L E D S E R U M

Majid Ali, Madhava P Ramanarayanan

Allergenic factors are isolated from antigen extracts by preparing a column with pooled serum from patients with allergy to a given aller- gen system and passing over this column a pool of allergen extracts from different sources. Aller- gen specific immunoglobulin antibodies in purified form are obtained by forming an antigen-specific antibody complex from serum containing the antibodies and a material con- taining the antigen, recovering the complex and disassociating it, forming a second complex of the antigen with an excess of a second antibody so as to realize a combination of the second com- plex, free first specific antibody and free second specific antibody and then separating the second complex from the free first and second anti- bodies.